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Abstract 13 
The human DEAD-box helicase 3 (DDX3) has been shown to contribute to type I interferon induction 14 
downstream of anti-viral pattern recognition receptors (PRRs). It binds to TANK-binding kinase 1 (TBK1) 15 
and IB-kinase- (IKK, the two key kinases mediating activation of Interferon regulatory factor (IRF) 3 16 
and IRF7. We previously demonstrated that DDX3 facilitates IKK activation downstream of RIG-I and 17 
then links the activated kinase to IRF3. In this study, we probed the interactions between DDX3 and other 18 
key signalling molecules in the RIG-I pathway and identified a novel direct interaction between DDX3 and 19 
TRAF3 mediated by a TRAF-interaction motif in the N-terminus of DDX3, which was required for TRAF3 20 
ubiquitination. Interestingly, we observed two waves of K63-linked TRAF3 ubiquitination following RIG-21 
I activation by Sendai Virus infection (SeV), both of which were suppressed by DDX3 knockdown. We 22 
also investigated the spatiotemporal formation of endogenous downstream signalling complexes containing 23 
the MAVS adaptor, DDX3, IKK, TRAF3 and IRF3. DDX3 was recruited to MAVS early after SeV 24 
infection, suggesting it might mediate subsequent recruitment of other molecules. Indeed, knockdown of 25 
DDX3 prevented formation of TRAF3-MAVS and TRAF3-IKKcomplexes. Based on our data, we 26 
propose that early TRAF3 ubiquitination is required for formation of a stable MAVS-TRAF3 complex, 27 
while the second wave of TRAF3 ubiquitination mediates IRF3 recruitment and activation. Our study 28 
characterises DDX3 as a multifunctional adaptor molecule that coordinates assembly of different TRAF3, 29 
IKK and IRF3-containing signalling complexes downstream of MAVS. Additionally, it provides novel 30 
insights into the role of TRAF3 in RIG-I signalling.  31 
 32 
Short summary 33 
We identified a novel direct interaction between DDX3 and TRAF3 important for signalling by the anti-34 
viral pattern recognition receptor RIG-I, and characterised spatiotemporal formation of endogenous 35 
downstream signalling complexes, providing novel insights into the role of TRAF3 in RIG-I signalling. 36 
 37 
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Abbreviations: Aa, amino acid; CK, Casein Kinase; GST, Glutathione-S-Transferase; HA, hemagglutinin; 43 
HEK, Human embryonic kidney; IFN, interferon; IKK, IkB kinase; IP, immunoprecipitation; IRF, 44 
interferon regulatory factor; MAVS, mitochondrial antiviral signalling; mt, mutant; Ni-Ag, Nickel- 45 
Agarose; NSC, non-silencing control; PRR, pattern recognition receptor; RIG, retinoic-acid inducible gene; 46 
RLH, RIG-like Helicase; SeV, Sendai Virus; shRNA, short hairpin RNA; siRNA, small interfering RNA; 47 
TBK, TANK-binding kinase; TLR, Toll-like receptor; TRAF, TNF receptor associated factor; WB, western 48 
blot; wt, wild-type 49 
Introduction 50 
During viral infections, viral nucleic acids are detected by a range of intracellular pattern recognition 51 
receptors (PRRs). A hallmark of these anti-viral PRRs is the activation of signalling pathways that lead to 52 
production of type I interferons. Induction of type I IFN gene promoters requires interferon regulatory factor 53 
(IRF)3 or IRF7, transcription factors that dimerise and translocate into the nucleus following 54 
phosphorylation of crucial serine residues. The IKK-related kinases IKKϵ and TBK1 phosphorylate IRF3 55 
and IRF7 downstream of anti-viral PRRs, including Toll-like receptor (TLR)3, the RIG-like helicases 56 
(RLHs), and cytoplasmic DNA receptors[1-4]. Interestingly, it was demonstrated that all TLRs activate 57 
TBK1 and IKKϵ via a pathway dependent on MyD88 and the canonical IKKs, yet IRF3 phosphorylation 58 
and induction of type I IFNs only occur downstream of TLR3 and TLR4 [5]. This suggested that activation 59 
of the IKK-related kinases is required but not sufficient for IRF3 activation, and it has been proposed that 60 
an additional adaptor molecule links the activated IKK-related kinases to IRF3 in cells [5]. We have 61 
previously demonstrated that the DEAD-box protein DDX3 facilitates IKKϵ activation, and also links 62 
activated IKKϵ to IRF3 to enable IRF3 phosphorylation [6]. As a DEAD-box helicase, DDX3 can act as an 63 
RNA remodelling enzyme and has functions in RNA metabolism [7]. However, its role in IRF3 activation 64 
and type I IFN induction did not require its enzymatic activity [8, 9], in line with a function as signalling 65 
adaptor. There are two functional DDX3 genes in the human genome, one on the X-chromosome (DDX3X) 66 
and one on the Y-chromosome (DDX3Y). This work, and also our previous work [6, 8], has been carried 67 
out with DDX3X, which we refer to as DDX3 for the remainder of the text. DDX3Y protein was proposed 68 
to only be expressed in the male germline [10]. Another key signalling molecule for IFN induction is 69 
TRAF3, which is part of the TLR and RLH pathways and required for IRF3 activation [11, 12]. TRAF3 70 
has also been suggested as a prime candidate for providing the missing link between IKK/TBK1 and IRF3 71 
activation [5]. On the other hand, a lot of studies support an upstream role for TRAF3 in the activation of 72 
IKK/TBK1, e.g. it has been shown to bind to the adaptors TRIF and MyD88 which mediate TLR signalling 73 
to IRF3/7 activation [12], as well as to MAVS which carries out an equivalent adaptor function in the RLH 74 
signalling pathway [13], and to facilitate recruitment of IKK/TBK1 to these adaptors. TRAF3, like all 75 
TRAF proteins, can contribute to signalling pathways either by acting as an adaptor molecule or through 76 
its E3 ligase activity, which catalyses the addition of K63-linked ubiquitin chains to specific substrates [14]. 77 
K63-linked ubiquitin chains provide docking sites for the recruitment of additional signalling molecules, 78 
and therefore constitute important posttranslational modifications that regulate signal transduction events. 79 
This is in contrast to K48-linked ubiquitination which marks proteins for proteasomal degradation. 80 
Activation of TRAF3 involves its oligomerisation followed by K63-linked auto-ubiquitination, which has 81 
been shown to be required for IFN induction [15]. It is not fully understood how exactly ubiquitination of 82 
TRAF3 contributes to IFN induction, but it was suggested to mediate interaction with IKK/TBK1 [16]. In 83 
summary, while the overall importance for TRAF3 in IFN induction pathways downstream of several 84 
different PRR pathways is well established, its exact placement in the pathway and the role of its E3 ligase 85 
activity are not clear.  86 
In this study, we describe the identification of a novel direct interaction between DDX3 and TRAF3 through 87 
an N-terminal TRAF-binding motif in DDX3. We show that the DDX3-TRAF3 interaction is required for 88 
3 
 
K63-linked TRAF3 ubiquitination and ifnb promoter activation following activation of the RIG-I pathway. 89 
We also studied the spatiotemporal formation of endogenous signalling complexes following activation of 90 
the RIG-I pathway by Sendai virus infection. Our data suggest a non-linear relationship for DDX3 and 91 
TRAF3 in the pathway, and supports the existence of two distinct TRAF3 ubiquitination events which may 92 
be required for the formation of different signalling complexes. Thus, our data could help to explain the 93 
ambiguity surrounding the positioning of TRAF3 in IRF3 activation pathways. Most importantly though, 94 
it identifies an additional novel function for DDX3 in the coordination of multiple signalling complexes 95 
following RIG-I activation by viral infection.  96 
 97 
Experimental 98 
 99 
Plasmids, recombinant proteins and antibodies 100 
The expression constructs pCMV-HA-DDX3, pCMV-Myc-DDX3, pHis2-DDX3 (full-length and 101 
truncations) and pGST2-DDX3 have been described in our previous studies [6, 8]. The P142/E144A 102 
mutation was introduced into pCMV-HA-DDX3 and pHis-DDX3 (1-408) following instructions for the 103 
QuikChange Site-Directed Mutagenesis Kit (Agilent), except for using Pfusion™ HiFi polymerase (New 104 
England Biolabs). Introduction of the point mutations appeared to change mobility of the DDX3 protein in 105 
SDS-PAGE. However, the constructs have been fully sequenced to rule out additional mutations and 106 
sequencing confirmed its identity. IKK–flag, MAVS-flag and TRAF3-flag plasmids were kindly provided 107 
by Dr Kate Fitzgerald (University of Massachusetts Medical School, Worcester, MA). Plasmids for 108 
TRAF3-flag truncations were kindly provided by Prof Carl Ware (Sandford Burnham Medical Research 109 
Institute) [17], the plasmid for the TRAF3 C68A/H70A mutant was a kind gift from Prof Michael Karin 110 
(University of California, San Diego). Constructs for flag-Sintbad, flag-TANK and flag-NAP1 were 111 
provided by Dr Felix Randow (MRC Laboratory of Molecular Biology, Cambridge, UK) [18]. The 112 
expression construct for HA-tagged K63o(nly) Ubiquitin was provided by Dr Marion Butler (NUI 113 
Maynooth, Ireland). Recombinant TRAF3 was purchased from Novus Biologicals. The IKKϵ/TBK1 114 
inhibitor BX795 was purchased from Invivogen Europe (Cayla, France).   115 
The antibodies used were anti-flag M2 mAb (Sigma-Aldrich), anti-Myc mAb clone 9E10 (Sigma-Aldrich), 116 
anti-HA mAb (Covance), anti-DDX3 (Santa Cruz or Bethyl Laboratories), anti-Cardif (MAVS) (pAb 117 
AT107, Enzo Life Sciences), anti-TRAF3 (Santa Cruz), anti-IKK (Abcam, Cambridge, UK), anti-IRF3 118 
(IBL), anti-His (Sigma-Aldrich), anti K63-Ubiquitin (Cell Signaling Technologies), and anti-GST 119 
(Promega). Sendai Virus Cantell strain was obtained from Charles River Laboratories and used at a 120 
concentration of 80 HA U/ml.  121 
 122 
Cell culture and Transfection 123 
HEK293T and A549 cells were maintained in Dulbecco’s Modified Eagle Medium (DMEM) with 124 
Glutamax™ (Gibco), supplemented with 10% foetal calf serum and 50 ng/ml gentamycin (Sigma-Aldrich). 125 
Transient DNA transfections for immunoprecipitations and pull-downs were performed using the Calcium 126 
Phosphate method. Total amount of DNA was kept constant by addition of empty vector.  127 
 128 
shRNA knockdown of DDX3 129 
Lentiviral particles were generated by transfecting HEK293T cells with either pTRIPZ shDDX3 130 
(V2THS_228965, Thermo Scientific) or the corresponding non silencing control (NSC), and the packaging 131 
vectors psPAX2 and pMD2.G in the presence of chloroquine sulfate (5 µM). 16 h after transfection, the 132 
supernatant was removed and 5 ml fresh medium was added. Lentivirus-containing supernatants were 133 
harvested 24 h and 48 h and concentrated using PEG-precipitation. For generating knockdown cells, A549 134 
or HEK293T cells were plated at 3x105 cells/ml into a 6wp. 24h later the medium was replaced with 1 ml 135 
medium containing 4 µg/ml protamine sulphate. shDDX3 or NSC lentivirus was added at an MOI of 10. 136 
To create stable cell lines, the medium was replaced 24 h after transduction with 2 ml culture medium 137 
containing 1.5 µg/ml puromycin. After selection, the cells were also routinely kept in culture in the presence 138 
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of puromycin. For use in experiments, cells were cultured in the absence of puromycin and DDX3 139 
knockdown was induced by the addition of 0.5 µg/ml doxycycline for 48 h. 140 
siRNA knockdown of TRAF3 141 
For siRNA knockdown of endogenous human TRAF3, the Dharmacon siGENOME SMARTpool TRAF3 142 
or a non-targeting control SMARTpool were used (Thermo Fisher). Approximately 4x105 HEK293T cells 143 
were transfected with the SMARTpool siRNA (25nM) in 6wp using Lipofectamine™ 2000 (Invitrogen), 144 
according to manufacturer's instructions. 48 h after transfection, cell lysates were prepared, used for co-145 
immunoprecipitations, and analysed by SDS–PAGE and immunoblotting. 146 
 147 
GST or His pull-down assays 148 
Bacterial expression constructs for His- or GST-tagged proteins were transformed into E. coli BL21 (DE3). 149 
Protein expression was induced by IPTG, and recombinant proteins were purified using either Nickel-150 
Agarose (Qiagen) or Glutathione-Sepharose (Chromatrin Ltd, Dublin, Ireland). For pull-downs, equal 151 
amounts of the different His- or GST- tagged fusion proteins were used, as estimated by SDS–PAGE and 152 
Coomassie staining prior to use. Cell lysates containing flag-tagged protein expressed in HEK293T cells 153 
were incubated with the purified His- or GST-tagged proteins coupled to Nickel-Agarose or Glutathione-154 
Sepharose respectively. Alternatively, 2 μg of recombinant TRAF3 was used in the pulldown with His-155 
DDX3. Protein complexes were precipitated and washed thoroughly, before being subjected to SDS–PAGE 156 
and Western-Blot analysis. Control pulldowns were carried out with GST protein coupled to Glutathione-157 
Sepharose or empty Ni-Agarose beads for GST- and His-pulldowns respectively. 158 
 159 
Co-immunoprecipitation assays  160 
Co-immunoprecipitations were performed from cell lysates of transiently transfected HEK293T cells, 161 
which were harvested 24 h after transfection. Alternatively, for endogenous co-IPs, lysates from A549 cells 162 
seeded in 10 cm dishes were prepared following SeV infection. Cells were lysed in IP lysis buffer (50mM 163 
Hepes pH 7.4, 150 mM NaCl, 2 mM EDTA, 1% NP-40, 10% Glycerol, 10 mM NaF, 10 mM DTT, protease 164 
inhibitors). Cell lysates were incubated with 20 μl of Flag-M2 Agarose (Sigma-Aldrich) or Protein G 165 
agarose (Sigma-Aldrich) that had been pre-coupled with 2 μl of the relevant antibodies at 4 °C overnight 166 
and blocked with 5% BSA. The immunoprecipitated protein complexes were washed thoroughly and then 167 
eluted by boiling in Laemmli sample buffer, before being subjected to SDS–PAGE and Western-Blot 168 
analysis. 169 
 170 
Detection of endogenous TRAF3 ubiquitination 171 
HEK293T cells (shDDX3 or NSC shRNA) were lysed in RIPA buffer following infection with SeV. Cell 172 
lysates were boiled for 5min in the presence of 1% SDS. TRAF3 was immunoprecipitated from the 173 
denatured cell lysates, and precipitates were subjected to SDS-PAGE and Western Blot analysis with an 174 
antibody specific for K63-linked ubiquitin chains (Cell Signaling Technologies). 175 
 176 
Reporter gene assays 177 
Ifnb promoter induction was measured in HEK293 cells seeded into 96-well plates (2 x 104 cells per well) 178 
and transfected 24 h later with expression vectors and luciferase reporter gene constructs, using GeneJuice 179 
(Merck/Millipore). 60 ng of an ifnb promoter Firefly luciferase reporter gene construct was used in 180 
conjunction with 20 ng of a pGL3-Renilla luciferase construct (both provided by Andrew Bowie, Trinity 181 
College Dublin). The total amount of DNA transfected was kept constant at 230ng/well by addition of 182 
matching empty vector DNA. Firefly and Renilla Luciferase activity was measured 24 h after transfection. 183 
Alternatively, cells were infected with SeV 24 h after stimulation and harvested after a further 16 h. Renilla 184 
Luciferase readings were used to normalise for transfection efficiency. Data are expressed as mean fold 185 
induction ± SD relative to control levels, for an individual experiment performed in triplicate.   186 
 187 
Data representation  188 
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All data shown are representative of at least two independent repeat experiments, most are representative 189 
of 3-5 repeat experiments. Luciferase reporter gene assays are representative of at least 3 independent repeat 190 
experiments. Where a black box has been placed around Western Blot Results, this indicates that they were 191 
taken from the same original autorad exposure, and can thus be directly compared for intensity. Any 192 
adjustments for brightness and contrast have been applied evenly across the whole (boxed) panel. 193 
 194 
 195 
 196 
Results 197 
 198 
DDX3 directly interacts with TRAF3  199 
Our previous papers demonstrated that DDX3 is a positive regulator of type I IFN production in antiviral 200 
PRR signalling pathways [6, 8], which has also been confirmed by others [9, 19-21]. We showed that DDX3 201 
directly interacts with IKKϵ and IRF3, and thereby facilitates IRF3 phosphorylation by IKKϵ [6]. During 202 
this research that aimed to place DDX3 firmly into the signalling pathway leading to type I IFN induction 203 
downstream of RIG-I, we also tested whether DDX3 interacts with other important signalling molecules in 204 
this pathway. We expressed flag-tagged IKKϵ (as a positive control), MAVS, Sintbad, NAP1, TANK and 205 
TRAF3 in HEK293 cells and carried out pull-down assays with either  recombinant GST-tagged or His-206 
tagged DDX3. GST-DDX3 pulled down IKKϵ as expected; and it also interacted with TRAF3 and (weakly) 207 
with Sintbad, but not with TANK or NAP1 (Figure 1A). Despite the fact that a larger amount of GST 208 
protein compared to GST-DDX3 protein was present in control pulldowns (GST and GST-DDX3 signals 209 
shown in Figure 1A were detected on the same autoradiograph), we did not observe binding of TRAF3, 210 
IKK or Sintbad to the GST control, indicating that the observed interactions were specific for DDX3. In 211 
pulldown experiments with His-tagged DDX3, we also confirmed an interaction with MAVS (Figure 1A), 212 
which has previously been described by Oshiumi et al. [20]. In pulldowns with His-tagged DDX3, control 213 
pulldowns were carried out with empty Ni-Agarose beads (NiAg). There was no non-specific binding of 214 
MAVS to the Ni-Agarose matrix, again suggesting a specific interaction with DDX3. We were particularly 215 
interested in the observed interaction with TRAF3, because TRAF3 is a crucial signalling molecule for the 216 
activation of IRF3. We therefore confirmed and mapped the DDX3-TRAF3 interaction using pulldown 217 
assays with recombinant His-tagged DDX3 truncations (Figure 1B). Full-length His-tagged DDX3 (aa 1-218 
662) pulled down ectopically expressed flag-tagged TRAF3 from HEK293 cell lysates as expected, and the 219 
N-terminal domain of DDX3 (aa 1-408) also pulled down flag-TRAF3, while the C-terminal domain of 220 
DDX3 (aa 409-662) did not. Further truncations of the N-terminal domain revealed that TRAF3 still 221 
interacted with DDX3 139-408, but not with DDX3 172-408 (Figure 1B). The interaction of TRAF3 with 222 
the 139-408 DDX3 truncation made it unlikely that the this interaction is bridged by IKKϵ, as IKKϵ fails 223 
to interact with the 139-408 truncation mutant (it binds to a region between amino acids 100 and 110 of 224 
DDX3) [6]. To address the question whether DDX3 and TRAF3 directly interact, we next carried pulldown 225 
assays using purified recombinant His-tagged DDX3 and GST-tagged TRAF3 purchased from Novus 226 
Biologicals. As shown in Figure 1C, recombinant GST-TRAF3 was pulled down with His-tagged DDX3, 227 
but did not bind to Ni-Agarose beads in the absence of His-DDX3, indicating that DDX3 and TRAF3 can 228 
directly interact. We next determined which domain of TRAF3 mediates binding to DDX3. To this end, we 229 
expressed different flag-tagged TRAF3 truncation mutants in HEK293T cells and immunoprecipitated them 230 
with an anti-flag antibody. In these experiments, endogenous DDX3 was pulled down with full-length 231 
TRAF3 (1-570) and the truncations 114-570 and 259-570 (Figure 1D). DDX3 did not appear to interact 232 
with TRAF3 1-381 or 389-570 (Figure 1D). Because the interaction bands observed in this IP were 233 
relatively weak, we also carried out pulldown assays with recombinant His-tagged DDX3 coupled to Ni-234 
Agarose beads and lysates from HEK293T cells expressing the different flag-tagged truncation mutants. 235 
These pulldown experiments confirmed results from the immunoprecipitation, with TRAF3 1-570 (full-236 
length), 114-570 and 259-570 being pulled down by His-DDX3 and no interactions observed for TRAF3 237 
1-381 and 389-570 (Figure 1E). This data suggests that the N-terminal RING-finger and Zinc-finger 238 
domains of TRAF3 are dispensable for DDX3 binding. 239 
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 240 
Identification of a TRAF3 binding motif in DDX3  241 
Our pulldown data suggested that a region in DDX3 between aa 139 and 172 is required for TRAF3 binding 242 
(Figure 1B). Using a Eukaryotic Linear Motif (ELM) search [22], we identified a potential TRAF-binding 243 
motif within this region, namely 142-PSERLE-147. We mutated proline 142 (P142) and glutamic acid 144 244 
(E144) to alanine in order to generate a TRAF-binding site mutant of DDX3 (Figure 2A). We then tested 245 
this P142A/E144A mutant in comparison to wild-type DDX3 in immunoprecipitation and pulldown assays 246 
with TRAF3 to confirm that mutation of this putative TRAF-binding motif in DDX3 prevents TRAF3 247 
binding (Figure 2B-D). Of note, we observed that the P142A/E144E mutant migrated slightly faster in SDS-248 
PAGE than wild-type DDX3 (Figure 2B-D). This unexpected change in apparent molecular weight 249 
occurred for both the P142A/E144E mutant generated in pCMV-HA DDX3 (used in Figure 2B and 2C) 250 
and the P142A/E144E mutant generated in the pHis DDX3 (1-408) vector (used in Figure 2D). Both 251 
constructs were independently generated and sequence verified, ruling out that this change in apparent 252 
molecular weight is due to additional mutations/truncations. To test the effect of the mutation on TRAF3 253 
binding, we first carried out immunoprecipitations with flag-tagged TRAF3 and HA-tagged wild-type or 254 
mutant DDX3 co-expressed in HEK293T cells. When we immunoprecipitated TRAF3 with an anti-flag 255 
antibody, only wild-type DDX3 but not the P142A/E144E mutant DDX3 co-immunoprecipitated (Figure 256 
2B). In the reciprocal immunoprecipitation, using a HA-antibody against DDX3, TRAF3 also co-257 
immunoprecipitated only with wild-type but not mutant DDX3 (Figure 2C). Importantly, flag-tagged 258 
TRAF3 and HA-DDX3 were also expressed alone in the absence of the other binding partner to rule out 259 
non-specific pulldown by the flag or HA antibodies (lanes 1-3 in each experiment). Finally, we also 260 
generated the P142A/E144E mutation in His-tagged (1-408) DDX3 for use in pulldown assays with 261 
recombinant protein purified from E.coli. Only wild-type (wt) but not mutant (mt) His-DDX3 (1-408) 262 
coupled to Ni-agarose beads pulled down flag-TRAF3 from cell lysates (Figure 2D). In summary, three 263 
different binding assays demonstrated that mutation of the identified putative TRAF-binding motif in 264 
DDX3 abrogates the interaction with TRAF3. This further confirms a direct interaction between DDX3 and 265 
TRAF3, and we next set out to probe the functional consequences of this DDX3-TRAF3 interaction.  266 
 267 
The DDX3-TRAF3 interaction is required for full activation of the ifnb promoter 268 
DDX3 and TRAF3 are both intermediates in the signalling pathway leading to IRF3 activation and ifnb 269 
promoter activation downstream of anti-viral PRRs. In addition, we previously showed that DDX3 interacts 270 
directly with IKK to promote IRF3 phosphorylation. Knockdown of DDX3 reduced IKK and Sendai 271 
virus-mediated IRF3 phosphorylation and ifnb promoter activation [6, 8]. An IKK-TRAF3 interaction has 272 
also been shown to be required for IRF3 activation and ifnb promoter induction [16]. Thus, we first 273 
determined relative activation levels of the ifnb promoter when TRAF3, IKK and DDX3 were expressed 274 
separately or in combination (Figure 3A). Consistent with published data, TRAF3 and DDX3 were unable 275 
to induce promoter activation by themselves (columns 2 and 3). Co-expression of DDX3 and TRAF3 was 276 
also not sufficient to induce ifnb promoter activation (column 6). There was a slight enhancement when 277 
IKK and TRAF3 were co-expressed together (column 5) in accordance with previously published studies 278 
[11, 23]. DDX3 and IKK co-expression led to a strong enhancement of ifnb promoter activation (about 6-279 
fold increase compared to IKK alone, column 8), as shown in our previous publications [6, 8]. Addition 280 
of TRAF3 enhanced this activation further, meaning that co-expression of TRAF3, IKK and DDX3 led to 281 
strongest activation of the ifnb promoter (column 7).  282 
We next compared effects of wild-type DDX3 and the P142A/E144A TRAF3-binding site mutant of DDX3 283 
on ifnb promoter activation (Figure 3B and 3C). As in Figure 3A, expression of wild-type (wt) DDX3 284 
further enhanced ifnb promoter activation induced by IKK and TRAF3 co-expression (Figure 3B, dark 285 
grey bar). However, co-expression of the P142A/E144E mutant DDX3 (mt) (light grey bar) did not enhance 286 
ifnb promoter activation compared to activation by IKK/TRAF3 (black bar) (Figure 3B). Similar results 287 
were obtained when ifnb promoter activation was induced by SeV infection, triggering the signalling 288 
pathway at the level of RIG-I and in a more physiological manner (Figure 3C). Overexpression of wild-289 
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type DDX3 (wt) clearly enhanced SeV-induced ifnb promoter activation, while P142A/E144E DDX3 (mt) 290 
only showed a slight effect. Taken together, these results suggest that DDX3, IKK and TRAF3 cooperate 291 
to achieve full activation of the ifnb promoter. They also demonstrate that the DDX3-TRAF3 interaction is 292 
required for DDX3 to exert its positive effect on ifnb promoter activation downstream of RIG-I.  293 
 294 
DDX3 facilitates TRAF3 ubiquitination.  295 
We next wondered whether DDX3 regulates TRAF3 activation, one of the main indicators of which is K63-296 
linked ubiquitination. TRAF3 K63-ubiquitination is required for induction of type I interferon, with 297 
ubiquitination most likely mediated by TRAF3’s own E3 ligase activity (auto-ubiquitination) following its 298 
oligomerisation. Thus, we tested whether DDX3 affects TRAF3 ubiquitination. For initial experiments, we 299 
used an overexpression construct for Ha-tagged ubiquitin mutated at all lysine residues apart from Lysine 300 
63 (K63-only ubiquitin, K63o), which can therefore only be incorporated into K63-linked ubiquitin chains. 301 
We co-expressed flag-tagged TRAF3 and low levels of this K63o ubiquitin construct, and stimulated RIG-302 
I signalling by infection with Sendai Virus (SeV). Activation of the RIG-I pathway by SeV led to the 303 
appearance of a typical ubiquitination smear in the flag-TRAF3 blot (Figure 4A, lane 2), and co-expression 304 
of DDX3 enhanced this ubiquitination smear in both uninfected and SeV-infected cells (Figure 4A, lanes 3 305 
and 4). We next wanted to determine which region(s) of DDX3 are required for its effect on TRAF3 306 
ubiquitination, and tested our N-terminal and C-terminal DDX3 truncation mutants. Overexpression of flag-307 
TRAF3 caused a certain level of TRAF3 ubiquitination in the absence of stimulation, due to TRAF3 308 
oligomerisation and autoubiquitination, and full-length DDX3 (1-662) enhanced this in the absence of SeV 309 
infection (Figure 4A and 4B). To focus on direct effects of DDX3 on TRAF3, we tested the DDX3 310 
truncations in this setting. DDX3 (aa 139-662), which lacks the N-terminal IKKϵ binding site, was still able 311 
to facilitate TRAF3 ubiquitination, while a C-terminal truncation mutant, DDX3 (aa 1-408), was unable to 312 
do so, despite retaining TRAF3 and IKKϵ binding sites. Consistently, the DDX3 (aa 172-408) truncation 313 
also failed to enhance TRAF3 ubiquitination (Figure 4B). This data suggests that, along with its TRAF-314 
interaction motif, DDX3 also requires its C-terminal region between aa 409 and 662 to facilitate TRAF3 315 
ubiquitination. Next, we wanted to confirm the involvement of endogenous DDX3 in TRAF3 316 
ubiquitination, by using a cell line stably transduced with an inducible DDX3 shRNA plasmid to knock 317 
down DDX3 expression (Figure 4C).  In cells transduced with a non-silencing control (NSC) shRNA, 318 
TRAF3 ubiquitination was again triggered by its overexpression (lane 1), and SeV infection slightly 319 
enhanced this (lane 2). The DDX3 knockdown we achieved was suboptimal, however TRAF3 320 
autoubiquitination was still strongly reduced in DDX3 shRNA cells, both in the absence and presence of 321 
SeV infection (Figure 4C, lanes 3 and 4). We then wanted to confirm the importance of the TRAF3-322 
interaction motif in DDX3 for regulating TRAF3 ubiquitination. Thus, we transfected DDX3 knockdown 323 
cells with an shRNA-resistant DDX3 expression construct for either wild-type DDX3 or the P142A/E144A 324 
TRAF3-binding site mutant of DDX3 (Figure 4D). TRAF3 overexpression resulted in strong TRAF3 325 
autoubiquitination in NSC cells (Figure 4D, lane 1) but not DDX3 knockdown cells (Figure 4D, lane 4) as 326 
in Figure 4C. Reconstitution of knockdown cells with wild-type DDX3 restored TRAF3 ubiquitination 327 
(Figure 4D, lane 2), while reconstitution with the P142A/E144A TRAF3-binding site mutant of DDX3 did 328 
not (Figure 4D, lane 3). This suggests that a direct interaction between DDX3 and TRAF3 mediated by the 329 
TRAF-binding motif in the N-terminus of DDX3 is required for TRAF3 ubiquitination. 330 
Finally, we wanted to verify that DDX3 is indeed involved in mediating K63-linked ubiquitination of 331 
endogenous TRAF3 following stimulation of the RIG-I pathway, as our previous experiments were carried 332 
out with overexpressed TRAF3 and K63o ubiquitin. For Figure 4E, we therefore infected non-silencing 333 
control (NSC) cells and cells containing the DDX3 shRNA with SeV for different periods of time. We then 334 
immunoprecipitated endogenous TRAF3 from denatured cell lysates (ensuring that no cellular binding 335 
partners co-immunoprecipitate), and probed these samples in a western blot with an antibody specific for 336 
K63-ubiquitin chains, thus detecting endogenous K63-linked ubiquitin chains on endogenous TRAF3. 337 
Interestingly, we observed two waves of K63-linked TRAF3 ubiquitination in SeV-infected control (NSC) 338 
cells (Figure 4E): TRAF3 was K63-ubiquitinated 15-30min following SeV infection; ubiquitination had 339 
disappeared by the 1h time point, and re-appeared at the 2h and 4h time points following infection. In cells 340 
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with DDX3 knockdown, both early and late ubiquitination of TRAF3 was impaired (Figure 4E), confirming 341 
that DDX3 is indeed required for K63-linked ubiquitination of endogenous TRAF3 in the RIG-I pathway.  342 
 343 
DDX3 facilitates TRAF3 recruitment to MAVS 344 
As we have now demonstrated that DDX3 directly interacts with TRAF3 as well as IKKϵ and IRF3 [6] to 345 
facilitate ifnb promoter induction, we wondered in which order endogenous DDX3-, TRAF3- and IKKϵ-346 
containing signalling complexes form following stimulation of the RIG-I pathway. Investigation of 347 
endogenous signalling complexes downstream of RIG-I is not trivial due to the low expression levels of 348 
some signalling intermediates (such as IKK) and the quality of available antibodies. Very few studies are 349 
therefore available that describe the spatiotemporal formation of endogenous signalling complexes. We 350 
switched to A549 cells for these experiments, because they have a higher expression level of IKK than 351 
HEK293s and we previously successfully immunoprecipited endogenous DDX3-IKK-IRF3 complexes 352 
from these cells [6]. We infected A549 cells with SeV for time periods between 15min and 2h, followed by 353 
immunoprecipitation of endogenous DDX3 or endogenous TRAF3. We had difficulties to clearly detect 354 
IKK and TRAF3 in cell lysates, however bands at the expected molecular weight were detected in 355 
immunoprecipitated samples, where their levels are expected to be enriched. The MAVS antibody detected 356 
two specific bands, around 75 and 52 kDa, as previously described (Figure5 A-D) [24, 25]. The larger form 357 
presumably represents full-length MAVS and the other might represent the described MiniMAVS protein 358 
that lacks the N-terminal CARD domain [26].  359 
In these experiments, immunoprecipitation of endogenous DDX3 revealed that it is recruited to MAVS 360 
within 15min of SeV infection, while the interaction had disappeared by the 2h time point after infection 361 
(Figure 5A, top panel). IKKϵ co-immunoprecipitated with DDX3 30min-2h after SeV infection, thus this 362 
interaction appeared to be slightly delayed compared to the DDX3-MAVS interaction (Figure 5A, second 363 
panel). We were unable to detect the endogenous DDX3-TRAF3 interaction when immunoprecipitating 364 
with the DDX3 antibody. However, this interaction was clearly visible when we immunoprecipitated 365 
TRAF3, namely at 1h and 2h following SeV infection (Figure 5A, third panel). MAVS also co-366 
immunoprecipitated with TRAF3 at the same time points (Figure 5A, top panel), and IKKϵ co-367 
immunoprecipitated at the 2h time point after SeV infection (Figure 5A, second panel). We next decided to 368 
extend the infection period to 4h in order to investigate IRF3 recruitment. In our previous study, we 369 
observed IRF3 recruitment to DDX3 and IRF phosphorylation at this time point [6].  In order to fit all 370 
samples onto one gel, important for correctly identifying and directly comparing bands, we omitted the 371 
15min time point for this new set of experiments. Immunoprecipitation of DDX3 again revealed that the 372 
DDX3-MAVS interaction occurs early and transiently, as it was lost by 2h after infection, while the DDX3-373 
IKKϵ interaction persisted and increased at the 2h and 4h time points (Figure 5B, top and second panel). In 374 
TRAF3 immunoprecipitations, we observed a transient interaction between TRAF3 and MAVS 1h and 2h 375 
after infection, which had disappeared by the 4h time point, thus delayed compared to the DDX3-MAVS 376 
interaction (Figure 5B, top panel). The TRAF3-IKKϵ interaction was first detectable 2h after infection, but 377 
in contrast to the MAVS interaction persisted at the 4h time point (Figure 5B, second panel). The TRAF3-378 
DDX3 interaction was present between 1h and 4h following SeV infection (Figure 5B, third panel). 379 
Importantly, the DDX3-IRF3 and TRAF3-IRF3 interactions were first detectable 4h after SeV infection 380 
(consistent with our previous study), at a time when both proteins have been released from MAVS (Figure 381 
5B, bottom panel). In summary, these endogenous immunoprecipitations revealed an interesting temporal 382 
sequence of the recruitment and release of DDX3, IKKϵ and TRAF3 to the MAVS adaptor molecule 383 
following activation of the RIG-I pathway (summarised in Figure 7). It appears that recruitment of DDX3 384 
to MAVS is an early event (the only interaction we detected already 15min after infection, Figure 5A). It 385 
was therefore conceivable that DDX3 might facilitate recruitment of other signalling molecules, such as 386 
IKKϵ and TRAF3, into the MAVS complex. In order to test this hypothesis, we immunoprecipitated TRAF3 387 
from cells subjected to shRNA knockdown of DDX3. In control cells (NSC), DDX3, MAVS and IKKϵ co-388 
immunoprecipitated with TRAF3 1h after SeV infection as in our previous experiments. However, in DDX3 389 
knockdown cells (shDDX3), neither MAVS nor IKKϵ co-immunoprecipitated with TRAF3 (Figure 5C). 390 
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This suggested that DDX3 is required to facilitate TRAF3 recruitment to MAVS, where it might 391 
subsequently interact with IKKϵ. On the other hand however, we then also tested whether DDX3 392 
interactions are preserved in TRAF3 knockdown cells. To this end, we knocked down TRAF3 expression 393 
using an siRNA SMARTpool, followed by immunoprecipitation of DDX3. To our surprise, knockdown of 394 
TRAF3 also prevented the DDX3-MAVS interaction, while the DDX3-IKK interaction was at least 395 
partially preserved (Figure 5D). This data suggest a mutual regulation between DDX3 and TRAF3, as 396 
neither appears to stably interact with MAVS in the absence of the other.  397 
 398 
The E3 ligase activity of TRAF3 is required for MAVS binding and IRF3 recruitment 399 
As DDX3 enhanced TRAF3 ubiquitination, we also wished to address the importance of ubiquitination for 400 
the TRAF3 interactions we observed in Figure 5. To this end, we used a TRAF3 mutant deficient in E3 401 
ligase activity (C68A/H70A) [15], which is therefore unable to mediate ubiquitination of its substrates, 402 
including its own auto-ubiquitination. Ectopic expression of the wild-type TRAF3 construct led to 403 
spontaneous ubiquitination, which was enhanced slightly following SeV infection, while the C68A/H70A 404 
mutant did not display ubiquitination smears (Figure 6, bottom left panel, in whole cell lysates). We then 405 
immunoprecipitated wild-type TRAF3 (wt) or C68A/H70A TRAF3 using a flag-antibody and compared 406 
the co-immunoprecipitated proteins. As seen before, MAVS, DDX3, IKKϵ and IRF3 co-407 
immunoprecipitated with wild-type TRAF3 at various time points following SeV infection (Figure 6). 408 
Interestingly, the TRAF3 C68A/H70A mutant was strongly impaired in its ability to interact with MAVS 409 
(Figure 6, top right panel). Despite this, the TRAF3-IKKϵ and TRAF3-DDX3 interactions seemed to be 410 
largely unaffected by the C68A/H70A mutation (Figure 6, panels 2 and 3).  Another striking difference 411 
between wild-type TRAF3 and the C68A/H70A mutant was that IRF3 did not co-immunoprecipiate with 412 
the C68A/H70A mutant at the 4h time point after SeV infection (Figure 6, fourth panel on the right). This 413 
suggests that the E3 ligase activity/auto-ubiquitination of TRAF3 is required for its interaction with MAVS 414 
and also for recruitment of IRF3 into a separate soluble TRAF3 complex.  415 
 416 
Discussion 417 
In previous studies, we demonstrated that DDX3 mediates ifnb promoter activation following RIG-I 418 
engagement by SeV infection, and that it binds directly to IKKϵ and IRF3 in order to facilitate IRF3 419 
activation. This study adds another layer of complexity and suggests that DDX3 might coordinate assembly 420 
of several different multiprotein signalling complexes in the RIG-I pathway. We demonstrate that DDX3 421 
directly binds to TRAF3, which was required for DDX3 to enhance ifnb promoter activation. 422 
Mechanistically, our data indicates that DDX3 facilitates TRAF3 (auto)-ubiquitination and formation of a 423 
stable MAVS-TRAF3 signalling complex. Importantly, knockdown of DDX3 prevented endogenous K63-424 
linked ubiquitination of TRAF3 and formation of a signalling complex between endogenous TRAF3 and 425 
MAVS. 426 
 427 
The interaction between DDX3 and TRAF3 428 
We identified a novel TRAF3-binding motif in the intrinsically disordered N-terminal region of DDX3. 429 
This motif is conserved between DDX3X (the paralogue we investigated here) and DDX3Y, as well as 430 
DDX3 orthologues in other species. Mutation of this short linear motif in DDX3 abrogated TRAF3 binding 431 
and the ability of DDX3 to facilitate TRAF3 ubiquitination and enhance activation of the ifnb promoter. 432 
This clearly demonstrates that direct binding between DDX3 and TRAF3 is required for ifnb induction 433 
downstream of RIG-I. The C-terminus of DDX3 (aa 409-662) was also required for its effect on TRAF3 434 
ubiquitination. We can only speculate why this might be the case. There is some evidence that DDX3 might 435 
oligomerise through its C-terminal domain [27], and this could help to facilitate TRAF3 oligomerisation or 436 
the assembly of a multiprotein signalling complex. The C-terminus of DDX3 also contains a second binding 437 
site for IKK [6] and a MAVS binding site [20]. Thus, it is also possible that DDX3 mediates a functional 438 
interaction between TRAF3 and IKKand/or MAVS that is required for TRAF3 autoubiquitination. In any 439 
case, DDX3 likely enhances TRAF3 ubiquitination through the assembly or stabilisation of a protein 440 
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complex, as DDX3 itself does not have E3 ligase activity: it either facilitates TRAF3 autoubiquitination or 441 
recruitment of another E3 ligase that ubiquitinates TRAF3. Mapping of the DDX3 binding site on TRAF3 442 
showed that DDX3 binds to the C-terminus of TRAF3, which contains the TRAF domain. Specifically, 443 
DDX3 binding mapped to the TRAF-N domain, which mediates oligomerisation [14]. TRAF3 444 
oligomerisation is thought to trigger autoubiquitination [14], so this also supports our idea that DDX3 might 445 
facilitate TRAF3 autoubiquitination by promoting its oligomerisation.  446 
 447 
Sequential recruitment of signalling molecules to MAVS 448 
In co-immunoprecipitation experiments from SeV-infected cells, we analysed the spatiotemporal formation 449 
of different TRAF3-, IKK-, MAVS- and DDX3-containing signalling complexes following activation of 450 
the RIG-I pathway. Importantly, these are all fully endogenous protein interactions formed in response to 451 
physiological stimulation of RIG-I by SeV infection. The DDX3-MAVS interaction was the earliest 452 
interaction we were able to detect (15min after SeV infection), which suggested that DDX3 might be 453 
involved in recruiting downstream signalling molecules to MAVS. Indeed, in DDX3 knockdown cells, 454 
TRAF3 failed to bind MAVS and IKK(Figure 5C). However, to our complete surprise, in the reciprocal 455 
experiment, siRNA knockdown of TRAF3 also completely prevented DDX3 binding to MAVS (Figure 456 
5D), suggesting their relationship in this signalling pathway is not of a clear linear nature. Indeed, it has 457 
previously been shown that TRAF3 can directly bind to MAVS through TRAF interaction motifs (TIMs) 458 
in the N-terminal (aa 143-147) and C-terminal (aa 455-460) regions of MAVS [13, 28]. Saha et al. detected 459 
a constitutive interaction between TRAF3 and MAVS, whereas Paz et al. showed a SeV-inducible 460 
interaction between MAVS and a higher molecular weight form of TRAF3, presumably ubiquitinated 461 
TRAF3 [13, 28]. Upon closer examination of our co-IP data, we also observed a weak constitutive 462 
interaction between the lower molecular weight form of MAVS and TRAF3 in some experiments (e.g. in 463 
Figure 5B). Interestingly, the E3 ligase-deficient C68/70A mutant of TRAF3 also displayed this weak 464 
constitutive interaction with MAVS, suggesting that it does not require TRAF3 ubiquitination (Figure 6). 465 
We are thus proposing the following model (Figure 7): 1. An initial weak ubiquitin-independent interaction 466 
between MAVS and TRAF3 is required for recruiting DDX3 to MAVS, explaining why the DDX3-MAVS 467 
interaction was abolished in cells with TRAF3 knockdown. 2. DDX3 and IKKare recruited following SeV 468 
infection and interact functionally with TRAF3 to support its ubiquitination. This early TRAF3 469 
ubiquitination (as observed in Figure 4E) stabilises and/or re-organises the signalling complex with MAVS, 470 
making it much more readily detectable in our co-IPs. In DDX3 knockdown cells, TRAF3 ubiquitination 471 
is impaired and the (strong) MAVS-TRAF3 interaction cannot be detected (Figure 2C-E, Figure 5C). 3. 472 
DDX3 and TRAF3 are released from MAVS, but continue to interact with each other and with IKK(Figure 473 
5A and B). We hypothesise that removal of K63-ubiquitination from TRAF3 might be required for release 474 
from MAVS (based on our data in Figure 4E, where TRAF3 ubiquitination disappeared around 1h after 475 
infection). We detected DDX3-IRF3 and TRAF3-IRF3 interactions at the 4h timepoint (Figure 5B). This 476 
corresponds to the time frame when IRF3 phosphorylation takes place [6], suggesting that activation of 477 
IRF3 most likely occurs in this soluble signalling complex containing IKK, TRAF3, and DDX3. We 478 
cannot conclude with certainty that these proteins are all present in the same multiprotein complex rather 479 
than in several separate complexes, but due to the presence of non-overlapping binding sites for TRAF3, 480 
IKK and IRF3 in DDX3 and the potential for oligomerisation it is a conceivable possibility. This soluble 481 
complex also coincided with the second wave of TRAF3 ubiquitination we observed 2-4h after SeV 482 
infection (Figure 4E) and we therefore hypothesise that this ubiquitination is required for IRF3 recruitment. 483 
This is also supported by our finding that the E3 ligase-deficient C68/70A mutant of TRAF3 did not interact 484 
with IRF3 4h after SeV infection (Figure 6).  485 
 486 
The role of TRAF3 (ubiquitination) in interferon induction 487 
While it is widely accepted that TRAF3 is an essential component in signalling pathways leading to IRF3 488 
activation and IFN- induction [11, 29], its exact role in these pathways is still rather unclear. Most studies 489 
suggest that TRAF3 mediates recruitment of IKKϵ/TBK1 to upstream adaptor molecules, such as MAVS, 490 
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and thus activation of these kinases [11, 23, 30, 31]. Auto-ubiquitination of TRAF3 is required for IRF3 491 
activation and ifnb promoter induction [15], and several studies suggest that this ubiquitination mediates 492 
TRAF3 binding to IKKϵ/TBK1 [16, 23, 30, 32]. It has also been suggested that IKKϵ/TBK1 are 493 
ubiquitinated by TRAF3, with that ubiquitination being required for IKK/TBK1-mediated IRF3 activation 494 
and IFN induction [23, 33, 34]. However, it has more recently been suggested that TRAF3 is not required 495 
for IKKϵ/TBK1 activation, but that it rather mediates IRF3 activation downstream of these kinases [5]. So, 496 
does TRAF3 act upstream or downstream of IKK/TBK1? And what role does TRAF3 ubiquitination play? 497 
Our study did not set out to answer these questions, but it provides several novel insights and a potential 498 
explanation for the discrepancies in published findings. Our data suggest that the signalling pathway 499 
downstream of MAVS is by no means linear, as illustrated by our findings in DDX3 and TRAF3 500 
knockdown cells. TRAF3 is recruited into different protein complexes as signalling events downstream of 501 
MAVS progress, thus timing of experiments will greatly influence results. We propose that early (auto)-502 
ubiquitination of TRAF3 stabilises a signalling complex with MAVS. It is conceivable that this signalling 503 
complex contributes to the full and/or sustained activation of IKK/TBK1. For example, TRAF3 504 
knockdown prevented DDX3 recruitment to MAVS and the DDX3-IKK interaction also appeared to be 505 
more transient in TRAF3 knockdown cells (Figure 5D). Seeing as we have previously shown that DDX3 506 
enhances IKK activation in SeV-infected cells [6], TRAF3 could hereby indirectly affect IKK/TBK1 507 
activation in the RIG-I pathway. At the 4h time point after infection, TRAF3 had been released from 508 
MAVS, but continued to interact with IKK and DDX3 and started to interact with IRF3 (Figure 5B). 509 
Importantly, the E3-ligase deficient mutant of TRAF3 did not interact with IRF3 under these conditions 510 
(Figure 6), clearly indicating a role for TRAF3 (ubiquitination) in IRF3 recruitment (and therefore 511 
presumably activation). In alignment with this interaction data, we detected two waves of K63-linked 512 
TRAF3 ubiquitination after SeV-infection, and we suggest that these correspond to its involvement in these 513 
distinct signalling events.  The early wave, observed 15-30min after infection, is likely to stabilise the 514 
interaction with MAVS, which was also defective with the E3-ligase deficient mutant of TRAF3. Late K63-515 
linked TRAF3 ubiquitination occurred 2-4h after infection and is likely to support IRF3 recruitment and 516 
activation, as discussed above.   517 
In summary, our data suggest that TRAF3 and its ubiquitination have a dual role in RIG-I signalling, 518 
explaining why researchers have placed it at different levels in the signalling pathway in the past. Clearly, 519 
we still do not fully understand the complexities of the RIG-I signalling pathway and many open questions 520 
remain regarding the role and regulation of TRAF3 in this pathway. TRAF3 is targeted by several cellular 521 
and viral deubiquitinases (DUBs), and most of them, including DUBA and HSV-1 UL36, did not block 522 
IFN induction downstream of IKK/TBK1 [16, 32], which might suggest they specifically act on early 523 
TRAF3 ubiquitination. In future studies, it would be interesting to determine whether different DUBs target 524 
ubiquitinated TRAF3 specifically in the early versus late signalling complexes. Based on our data, we also 525 
hypothesise that TRAF3 might require deubiquitination for signalling to proceed, namely for it to be 526 
released from MAVS. It would be interesting to confirm this and to determine how this particular 527 
deubiquitination event is regulated.  528 
It is also possible that TRAF3 ubiquitination is regulated by phosphorylation. To our knowledge, there is 529 
no experimental evidence that IKK phosphorylates TRAF3. However, it has been shown to phosphorylate 530 
TRAF2, making it conceivable that other TRAFs could also be targets of its phosphorylation [35]. We have 531 
some evidence that inhibition of IKK’s kinase activity blocks TRAF3 ubiquitination at early time points 532 
(data not shown), suggesting that IKK either phosphorylates TRAF3 directly or phosphorylates another 533 
protein required for TRAF3 ubiquitination. Most interestingly, CK1another kinase whose kinase activity 534 
is regulated by DDX3, has recently been demonstrated to phosphorylate TRAF3 directly. This 535 
phosphorylation event promoted TRAF3 autoubiquitination and enhanced ifnb promoter activation [36]. 536 
Thus, it is possible that DDX3 links CK1 and/or IKK to TRAF3 to mediate its phosphorylation, similar 537 
to what we have described for IRF3 before, and that this promotes TRAF3 autoubiquitination [6]. However, 538 
DDX3’s role in facilitating TRAF3 ubiquitination clearly goes beyond stimulating the activity of CK1 539 
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and/or IKK, seeing as a direct interaction between DDX3 and TRAF3 mediated by DDX3’s TRAF-binding 540 
motif is required for its effect. 541 
 542 
DDX3 function in the RIG-I signalling pathway 543 
While our study provides interesting novel insights into the spatiotemporal regulation of RIG-I signalling 544 
and the role of TRAF3 as discussed above, our main focus was the function of DDX3. We identified a novel 545 
direct interaction between DDX3 and TRAF3 that is mediated by an interaction motif in the flexible N-546 
terminus of DDX3. This direct interaction between DDX3 and TRAF3 was required for TRAF3 547 
ubiquitination, the formation of a stable MAVS-TRAF3 complex, and activation of the ifnb promoter. 548 
Previously, we have shown that direct DDX3-IKK and DDX3-IRF3 interactions are also required for IRF3 549 
activation and activation of the ifnb promoter [6]. Furthermore, DDX3 can also directly bind to MAVS 550 
([20], Figure 1A and data not shown). It thus emerges that DDX3 can bridge several different interactions 551 
between important signalling molecules downstream of MAVS at different time points post infection. Our 552 
study therefore reveals the multifunctionality of DDX3 as a signalling adaptor in the RIG-I signalling 553 
pathway, reinforcing its characterisation as a key facilitator of the type I interferon induction pathway 554 
downstream of RIG-I.  555 
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Figure legends 
Figure 1. DDX3 interacts directly with TRAF3. 
(A) Flag-IKKϵ, flag-MAVS, flag-TRAF3, flag-Sintbad, flag-TANK or flag-NAP were ectopically 
expressed in HEK293T cells and cell lysates were prepared 24-48h after transfection. Recombinant GST-
DDX3 or GST (as a control) coupled to Glutathione Sepharose beads were then used to pull down these 
flag-tagged proteins from the cell lysates. After pulldowns, beads were thoroughly washed, boiled in SDS 
sample buffer and subjected to SDS-PAGE and Western Blot Analysis. GST and GST-DDX3 signals were 
detected on the same autorad film; this is indicated by the black box around the bottom two panels. His-
DDX3 coupled to Nickel-Agarose beads (NiAg) was used for the MAVS pulldown, with empty Ni-Ag 
beads used in the control pulldown. In all cases, cell lysates were run as input controls to confirm expression 
of the protein. (B) Recombinant His-tagged DDX3 truncation mutants coupled to Nickel-Agarose (Ni-Ag) 
beads were used to pull down flag-tagged TRAF3 from lysates of HEK293T cells that had been transfected 
with a TRAF3 expression construct for 24 h. Numbers indicate amino acid positions of DDX3 truncations, 
with 1-662 representing full-length DDX3.  Beads were thoroughly washed, boiled in SDS sample buffer 
and subjected to SDS-PAGE and Western Blot analysis with anti-flag and anti-His antibodies. Empty Ni-
Agarose beads (Ni-Ag) were used in a control pulldown, and expression of flag-TRAF3 in the cell lysate 
is shown in the input control. (C) Recombinant His-tagged DDX3 coupled to Nickel-Agarose beads or 
empty Ni-Agarose beads as a control (Ni-Ag) were incubated with 2 μg of recombinant GST-tagged TRAF3 
in lysis buffer. Beads were thoroughly washed, boiled in SDS sample buffer and subjected to SDS-PAGE 
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and Western Blot Analysis with anti-TRAF3 and anti-His antibodies. (D) Expression constructs for 
different flag-tagged TRAF3 truncations were transfected into HEK293T cells, as indicated (numbers 
represent amino acid positions). 1-570 represents full-length TRAF3. 24 h after transfection, cells were 
lysed and TRAF3 truncations were immunoprecipitated using anti-flag M2 Agarose. Immunoprecipitates 
were thoroughly washed, boiled in SDS sample buffer and subjected to SDS-PAGE and Western Blot 
analysis with antibodies against endogenous DDX3 and the flag epitope tag. L.C.: antibody light chain. (E) 
Full-length flag-tagged TRAF3 (1-570) or different TRAF3 truncation mutants were ectopically expressed 
in HEK293T cells and cell lysates were prepared 24 h after transfection. Recombinant His-DDX3 coupled 
to Nickel-Agarose beads was then used to pull down flag-tagged TRAF3 truncations from cell lysates. 
Precipitates were thoroughly washed, boiled in SDS sample buffer and subjected to SDS-PAGE and 
Western Blot analysis with the indicated antibodies. Expression of the different TRAF3 constructs in cell 
lysates is confirmed in the right panel (Input) and equal pulldown of His-DDX3 across all samples is 
confirmed in the bottom left panel.  
 
Figure 2. An N-terminal TRAF-binding motif in DDX3 mediates TRAF3 binding  
(A) Through an ELM (eukaryotic linear motif) search, we identified a putative TRAF binding motif 
between amino acid 141 and 147 in human DDX3(X). To test the functional importance of this motif, we 
mutated the proline (P) at position 142 and the glutamic acid (E) at position 144 to alanines (A) (142/144A 
mutant).  (B) Expression constructs for flag-TRAF3 and either Ha-DDX3 or the Ha-DDX3 P142/E144A 
mutant were transfected alone or in combination into HEK293T cells. 24 h after transfection, cells were 
lysed and TRAF3 was immunoprecipitated using anti-flag M2 Agarose. Immunoprecipitates were 
thoroughly washed, boiled in SDS sample buffer and subjected to SDS-PAGE and Western Blot analysis 
with the indicated antibodies. (C) As in (A), but Ha-DDX3 was immunoprecipitated with an anti-Ha 
antibody absorbed to Protein G sepharose. (D) Recombinant His-tagged DDX3 (1-408) coupled to Nickel-
Agarose (Ni-Ag) beads was used to pull down flag-tagged TRAF3 from lysates of HEK293T cells that had 
been transfected with a TRAF3 expression construct for 24 h. His-tagged 1-408 wildtype (wt) DDX3 was 
compared to 1-408 DDX3 carrying the P142/E144A mutation (mt), and empty Ni-Agarose beads were used 
in a control pulldown (Ni-Ag). Beads were thoroughly washed, boiled in SDS sample buffer and subjected 
to SDS-PAGE and Western Blot analysis with the indicated antibodies. TRAF3 expression in cell lysates 
is shown as an input control; and input and pulldown samples were detected on the same autorad film as 
indicated by the black box around the top panel.  
 
Figure 3. TRAF3 binding of DDX3 is required for ifnb promoter induction. 
(A) HEK293T cells were transfected with an ifnb promoter firefly luciferase reporter gene construct, a 
Renilla control luciferase construct, and expression constructs for flag-IKK, flag-TRAF3, and Ha-DDX3 
alone or in combination. Luciferase activity was measured 24h after transfection. Data are normalised to 
Renilla luciferase levels and expressed as mean fold induction relative to control levels ± standard deviation. 
Shown is one representative experiment of three, performed in triplicate. (B) The effects of wild-type DDX3 
(wt) (dark grey bar) and the P142/E144A Ha-DDX3 mutant (mt) (light grey bar) are compared on 
TRAF3/IKKinduced ifnb promoter activity measured by luciferase reporter assays as described in (A). 
Activation levels induced by TRAF3 (T3) and IKKalone are also shown for reference. (C) As in (B), but 
ifnb promoter activation was induced by infection with Sendai Virus (SeV) 16 h before measuring luciferase 
levels.  
 
Figure 4. DDX3 facilitates K63-linked TRAF3 ubiquitination 
(A) HEK293T cells were transfected with expression constructs for flag-TRAF3 and K63o Ubiquitin, with 
or without Ha-DDX3 as indicated. Cells were infected with SeV 30min prior to cell lysis where indicated. 
Cell lysates were subjected to SDS-PAGE and Western Blot Analysis with an anti-flag antibody (to detect 
TRAF3) and anti-Ha antibody (to detect DDX3). (B) As in (A), but cells were transfected with empty vector 
(EV) or expression constructs for either full-length Ha-DDX3 (1-662) or different Ha-tagged N- or C-
terminal DDX3 truncation mutants (numbers indicate amino acid  positions). Expression of these 
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truncations was confirmed by anti-Ha western blot on cell lysates (bottom panel). (C) DDX3 knockdown 
was induced in HEK293T cells stably transfected with pTRIPZ-shDDX3 (or a non-silencing control (NSC) 
pTRIPZ vector) through incubation with 0.5 ug/ml doxycyline for 48 h. 24 h after doxycycline addition, 
cells were transfected with expression constructs for flag-TRAF3 and Ha-K63o Ubiquitin. Cells were 
infected with SeV 30 min prior to cell lysis. Cell lysates were prepared and subjected to SDS-PAGE and 
Western Blot Analysis with anti-flag and anti-DDX3 antibodies. (D) As in (C), but DDX3 expression was 
reconstituted by co-transfection of shRNA-resistant expression constructs for either wildtype DDX3 (wt) 
or the 142/144A DDX3 mutant (mt). Similar expression levels of the wild-type and mutant DDX3 were 
confirmed by anti-Ha western blot (bottom panel).  (E) DDX3 knockdown was induced in HEK293T 
shDDX3 cells (or NSC controls) as in (C) and (D). Cells were then infected with SeV for the indicated 
periods of time. Cell lysates were prepared and boiled with SDS for 5 min to disrupt protein complexes. 
Subsequently, endogenous TRAF3 was immunoprecipitated and analysed by SDS-PAGE and Western Blot 
Analysis with an antibody specific for K63-linked ubiquitin chains. DDX3 knockdown was confirmed by 
western blotting on cell lysates, with anti-tubulin staining serving as loading control (bottom panel). 
Samples from NSC and shDDX3 cells were analysed on the same gel/blot, as indicated by the black boxes 
around panels. 
 
Figure 5. Spatiotemporal formation of different endogenous DDX3- and TRAF3-containing 
signalling complexes following RIG-I activation. 
(A and B) A549 cells were infected with SeV for the indicated time periods. Cell lysates were then prepared 
and either endogenous DDX3 or endogenous TRAF3 were immunoprecipitated. Immunoprecipitates (IP) 
were washed thoroughly and subjected to SDS-PAGE and Western Blot (WB) analysis with MAVS, IKK, 
DDX3 and TRAF3 antibodies. In (B) IRF3 recruitment was also analysed by western blotting. The MAVS 
antibody detected two bands, which presumably represent full-length MAVS and the shorter MiniMAVS 
protein. IKK and TRAF3 were difficult to detect in cell lysates, but bands at the correct molecular weight 
were detected in immunoprecipiations where they are expected to be enriched. All samples from one 
experiment (lysates and both immunoprecipitates) were run on the same gel/blot to allow for correct 
identification and direct comparison of bands. H.C.: antibody heavy chain, ns: non-specific band (C) DDX3 
knockdown was induced in A549 cells stably transfected with pTRIPZ-shDDX3 (or a non-silencing control 
(NSC) pTRIPZ vector) through incubation with 0.5 μg/ml doxycyline for 48h. Cells were then infected 
with SeV for the indicated time periods, followed by preparation of cell lysates and immunoprecipitation 
of endogenous TRAF3. Immunoprecipitates were washed thoroughly and subjected to SDS-PAGE and 
Western Blot Analysis with MAVS, IKK, DDX3 and TRAF3 antibodies. Lysates and IP samples were run 
on the same gel/blot and visualised on the same autorad, indicated by the black boxes around the panels. 
(D) A549 cells were transfected with TRAF3 siRNA (siTRAF3) or a non-silencing control oligo (NSC). 
Cells were infected with SeV for the indicated periods of time, and harvested 48 h after siRNA transfection. 
DDX3 was immunoprecipitated from cell lysates and immunoprecipitates were analysed by SDS-PAGE 
and Western Blot Analysis with MAVS, IKK, DDX3 and TRAF3 antibodies. Lysates and IP samples were 
run on the same gel/blot and visualised on the same autorad, indicated by the black boxes around the panels. 
 
Figure 6. TRAF3 E3 ligase activity is required for MAVS and IRF3 interaction. A549 cells were 
transfected with either flag-tagged wild-type (wt) TRAF3 or the E3-ligase deficient C68A/H70A mutant. 
24 h after transfection, cells were infected with SeV for the indicated time periods, followed by preparation 
of cell lysates and immunoprecipitation of flag-TRAF3 with anti-flag M2 agarose. Immunoprecipitates 
were washed thoroughly and subjected to SDS-PAGE and Western Blot Analysis with MAVS, IKK, 
DDX3, TRAF3 and IRF3 antibodies. Samples from wild-type (wt) and C68A/H70A mutant TRAF3-
transfected cells were run side-by-side on the same gel/blot, for both cell lysates (Input, left panels) and 
immunoprecipitates (IP, right panel) to ensure that we can directly compare bands for wild-type and mutant 
TRAF3.  
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Figure 7: Schematic summary of signalling events observed following stimulation of the Rig-I 
pathway. This schematic summarises the sequential interactions we observed when we 
immunoprecipitated endogenous DDX3 (black bars) or endogenous TRAF3 (grey bars) at different time 
points following SeV infection (Figures 5A and B). It also gives an indication of the temporal occurrence 
of TRAF3 ubiquitination as observed in Fig 4E (dark grey bars), and IKKϵ and IRF3 phosphorylation as 
previously observed (Gu et al, MCB 2013), in relation to these interactions. The drawing illustrates the 
composition of the different signalling complexes we propose based on our co-IP data. At the 4 h time 
point, DDX3, IKK and TRAF3 no longer interact with MAVS, but are interacting instead with IRF3. This 
suggests the presence of a soluble signalling complex that contains DDX3, IKK, TRAF3 and IRF3 and 
facilitates IRF3 activation. Formation of the MAVS-bound complex and the IRF3-containing complex seem 
to correlate with the early and late wave of K63-linked TRAF3 ubiquitination we observed. This is further 
supported by our finding that E3-ligase-deficient non-ubiquitinated TRAF3 did not interact with MAVS or 
IRF3 following SeV stimulation (Figure 6). 
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